Press Releases Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None2026202520242023202220212020 April 23, 2025 Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025 April 15, 2025 Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer April 10, 2025 Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting March 19, 2025 Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support March 5, 2025 Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update February 26, 2025 Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference February 5, 2025 Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference January 13, 2025 Protara Highlights Recent Updates and Anticipated 2025 Milestones January 8, 2025 Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference December 11, 2024 Protara Announces Closing of $100 Million Public Offering December 9, 2024 Protara Announces Pricing of $100 Million Public Offering December 9, 2024 Protara Announces Proposed Public Offering Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 37 - 48 of 137 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None2026202520242023202220212020 April 23, 2025 Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025 April 15, 2025 Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer April 10, 2025 Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting March 19, 2025 Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support March 5, 2025 Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update February 26, 2025 Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference February 5, 2025 Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference January 13, 2025 Protara Highlights Recent Updates and Anticipated 2025 Milestones January 8, 2025 Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference December 11, 2024 Protara Announces Closing of $100 Million Public Offering December 9, 2024 Protara Announces Pricing of $100 Million Public Offering December 9, 2024 Protara Announces Proposed Public Offering Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 37 - 48 of 137
April 23, 2025 Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025
April 15, 2025 Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer
April 10, 2025 Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting
March 19, 2025 Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
March 5, 2025 Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
February 5, 2025 Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
